Concurrent Investment Advisors LLC Has $98,000 Position in Altimmune, Inc. $ALT

Concurrent Investment Advisors LLC boosted its stake in Altimmune, Inc. (NASDAQ:ALT) by 16.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,258 shares of the company’s stock after acquiring an additional 3,565 shares during the period. Concurrent Investment Advisors LLC’s holdings in Altimmune were worth $98,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ALT. Bank of New York Mellon Corp boosted its holdings in shares of Altimmune by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock worth $945,000 after buying an additional 2,162 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in Altimmune by 20.3% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $67,000 after acquiring an additional 2,268 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Altimmune by 5.4% during the 1st quarter. MetLife Investment Management LLC now owns 46,870 shares of the company’s stock valued at $234,000 after acquiring an additional 2,396 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in Altimmune by 3.9% during the 1st quarter. Deutsche Bank AG now owns 79,851 shares of the company’s stock valued at $399,000 after acquiring an additional 3,026 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Price Performance

ALT opened at $4.04 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. Altimmune, Inc. has a 52-week low of $2.90 and a 52-week high of $11.16. The stock has a market capitalization of $356.57 million, a PE ratio of -3.42 and a beta of 0.07. The stock’s 50 day moving average price is $3.78 and its 200-day moving average price is $4.56.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. On average, equities research analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALT. JMP Securities decreased their price objective on Altimmune from $25.00 to $15.00 and set a “market outperform” rating for the company in a report on Thursday, July 10th. The Goldman Sachs Group upgraded Altimmune to a “strong sell” rating in a research report on Thursday, July 10th. B. Riley dropped their target price on Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. UBS Group decreased their price target on Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Monday. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.40.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.